The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators (COLLAT-COVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05932719
Recruitment Status : Recruiting
First Posted : July 6, 2023
Last Update Posted : July 10, 2023
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The COVID-19 pandemic has deeply and globally impacted usual procedures and patients management in cancer centers. The aim of this study is to set-up and collect indicators to follow-up the activities of different cancer pathologies before and during the pandemic. Patients loss' of chance will be analysed in term of diagnosis and access to care (surgery, antineoplastic treatments).

Data collection will focus on the analysis of 2 specific pathologies for French patients in the "Auvergne-Rhône Alpes" Area: peritoneal carcinosis and hepatocellular carcinoma.


Condition or disease Intervention/treatment
Hepatocellular Carcinoma Peritoneal Carcinoma Other: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators to Follow-up the Activities of Different Cancer Pathologies
Actual Study Start Date : December 1, 2022
Actual Primary Completion Date : December 1, 2022
Estimated Study Completion Date : December 1, 2024

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Peritoneal Carcinosis
Patients hospitalized for peritoneal carcinosis between 2017 and 2020.
 Other: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.

The following items will be collected

  • Diagnostic date
  • Diagnostic stage
  • Date of surgery
  • Date of surgery appointment
  • First antineoplastic treatment date
  • Last antineoplastic treatment date
  • Number of treatment cycles recommanded by MDTM
Hepatocellular Carcinoma
Patients hospitalized for hepatocellular carcinoma between 2017 and 2020.
 Other: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.

The following items will be collected

  • Diagnostic date
  • Diagnostic stage
  • Date of surgery
  • Date of surgery appointment
  • First antineoplastic treatment date
  • Last antineoplastic treatment date
  • Number of treatment cycles recommanded by MDTM


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Measure of patient loss of chance when comparing a set of activity indicators between 2020 and the average activities of previous periods (2017-2019) [ Time Frame: 24 months ]
    The difference between a set of different activity indicators will be compared between 2020 and the average activities of previous periods (2017-2019)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients hospitalized in France for peritoneal carcinosis or hepatocellular carcinoma between 2017 and 2020.
Criteria

Inclusion Criteria:

  • Patients hospitalized in France for peritoneal carcinosis or hepatocellular carcinoma between 2017 and 2020.

Exclusion Criteria:

  • Patients who did not allow the reuse of their medical data for research
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05932719


Locations
Layout table for location information
France
Hopital Lyon sud, Hospices civils de Lyon Recruiting
Pierre-Bénite, France, 69495
Contact: Julien PERON, MD    4 78 86 37 75 ext +33    julien.peron@chu-lyon.fr   
Sponsors and Collaborators
Hospices Civils de Lyon
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT05932719    
Other Study ID Numbers: 69HCL20_0697
First Posted: July 6, 2023    Key Record Dates
Last Update Posted: July 10, 2023
Last Verified: July 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hospices Civils de Lyon:
COVID-19
Cancer
Health Care Quality Indicators
hepatocellular carcinoma
peritoneal carcinosis
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
Coronavirus Infections
 Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases